Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2011 | Original Paper

Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma

Authors: Chel Hun Choi, Ji-Soo Lee, Seong Rim Kim, Yoo-Young Lee, Chul-Jung Kim, Jeong-Won Lee, Tae-Joong Kim, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2011

Abstract

Purpose

Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in many cancer and is emerging as a potential therapeutic target. Yet data on the expression of eIF4E in endometrial cancer are lacking.

Methods

Immunohistochemistry was used to evaluate the expression of eIF4E in 62 endometrial cancer surgical specimens. We subsequently evaluated whether inhibition of eIF4E by siRNA would have an impact on cell growth in endometrial cancer cell lines, using the MTT cell proliferation assay.

Results

According to a chosen cutoff value, 36 (58.1%) of 62 patient specimens scored as eIF4E positive. The positivity of eIF4E was significantly more frequent in tumors extending outside the uterus (stage III/IV vs. stage I/II, P = 0.027). Lastly, downregulation of eIF4E by siRNA reduced the growth of HEC-1A cells significantly but had a somewhat weaker effect in Ishikawa cells (P < 0.001).

Conclusions

Expressions of eIF4E correlated with prognosis of endometrial adenocarcinomas. Our results suggest that eIF4E might be a promising therapeutic target in endometrial cancer.

Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A (2001) Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 10:663–666PubMed

Byrnes K, White S, Chu Q et al (2006) High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243:684–690 discussion 691–682CrossRefPubMed

Darb-Esfahani S, Faggad A, Noske A et al (2009) Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 135:933–941CrossRefPubMed

De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199CrossRefPubMed

Gadducci A, Cosio S, Genazzani AR (2006) Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 58:242–256CrossRefPubMed

Graff JR, Zimmer SG (2003) Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20:265–273CrossRefPubMed

Graff JR, Konicek BW, Vincent TM et al (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638–2648CrossRefPubMed

Huang S, Houghton PJ (2002) Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 3:295–304PubMed

Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMed

Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59–65CrossRefPubMed

Li BD, Liu L, Dawson M, De Benedetti A (1997) Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79:2385–2390CrossRefPubMed

Li BD, McDonald JC, Nassar R, De Benedetti A (1998) Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227:756–761 discussion 761–763CrossRefPubMed

Li BD, Gruner JS, Abreo F et al (2002) Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235:732–738 discussion 738–739CrossRefPubMed

Meric F, Hunt KK (2002) Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 1:971–979PubMed

Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65CrossRefPubMed

Noske A, Lindenberg JL, Darb-Esfahani S et al (2008) Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 20:1409–1417PubMed

Pectasides D, Pectasides E, Economopoulos T (2007) Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33:177–190CrossRefPubMed

Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44CrossRefPubMed

Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312–319CrossRefPubMed

Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nature reviews 6:729–734CrossRefPubMed

Scheper GC, Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350–5359CrossRefPubMed

Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL (1998) Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77:2120–2128CrossRefPubMed

Soni A, Akcakanat A, Singh G et al (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782–1788CrossRefPubMed

Title: Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma
Authors: Chel Hun Choi
Ji-Soo Lee
Seong Rim Kim
Yoo-Young Lee
Chul-Jung Kim
Jeong-Won Lee
Tae-Joong Kim
Je-Ho Lee
Byoung-Gie Kim
Duk-Soo Bae
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0902-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues

Overexpression of T lymphoma invasion and metastasis 1 predict renal cell carcinoma metastasis and overall patient survival

Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer

RETRACTED ARTICLE: 67-kDa laminin receptor induces FasL expression and FasL-mediated apoptosis through the activation of c-Myc and the subsequent activation of the FasL promoter in human cholangiocarcinoma cells

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page